On Aug. 6, practice managers, clinicians and researchers gathered with ACR and RISE staff and volunteers to discuss the registry’s development and future.

Allison Plitman |
On Aug. 6, practice managers, clinicians and researchers gathered with ACR and RISE staff and volunteers to discuss the registry’s development and future.
Brandon May |
NEW YORK (Reuters Health)—A significant proportion of children with rheumatic diseases develop new-onset hypogammaglobulinemia and infections following treatment with the monoclonal antibody rituximab, according to new U.S. research. “Increased risk appeared to be mediated, at least in part, by exposure to pulse dose corticosteroids,” write Marc Natter, MD, of Harvard Medical School and Boston Children’s…
Reuters Staff |
(Reuters)—Europe’s drugs regulator said on Monday it was evaluating the use of Roche’s arthritis drug, tocilizumab, in hospitalized adults with severe COVID-19, its latest review of a potential coronavirus treatment. Tocilizumab, sold by Roche as Actemra and RoActemra, has shown promise in clinical trials in treating COVID-19, and was approved by U.S. health regulators in…
ATLANTA—The ACR is actively engaged with the U.S. Food & Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) drug shortage team as they work with the manufacturer to resolve current shortages of tocilizumab (Actemra). Demand for tocilizumab has outpaced supply, with demand increasing after the FDA’s June 24 Emergency Use Authorization (EUA) for…
One of the oldest treatment options in rheumatology, colchicine, may be an effective and inexpensive treatment to prevent complications in non-hospitalized patients with COVID-19, particularly in men, according to the results of large global study.
In July, the FDA approved the use of Octagam 10%, an intravenous immunoglobulin solution, to treat dermatomyositis in adults after an international study demonstrated the treatment’s safety and efficacy.
Abhimanyu Amarnani, MD, PhD, Nicole K. Zagelbaum Ward, DO, MPH, Lauren Mathias, MD, Nathan Lim, MD, Baljeet Rai, MD, Sky Wang, MD, & William Stohl, MD, PhD |
Pulmonary manifestations in patients with systemic lupus erythematosus (SLE) include pleuritis, acute pneumonitis, interstitial lung disease, pulmonary arterial hypertension, shrinking lung syndrome and diffuse alveolar hemorrhage (DAH). DAH is a rare, but devastating, complication of SLE, with high mortality rates. The incidence of DAH in SLE ranges from 0.6% to 5.4%, but the mortality rate…
Example 1 A cardiologist contacts a rheumatologist concerning a lupus patient. The rheumatologist sees the patient four weeks later for a complete examination. A 20-minute call is initiated to review the findings and the patient’s chart with the cardiologist. After the call is completed, the rheumatologist completes a verbal and written report to the patient’s…
The Rheumatology Research Foundation is proud to announce the launch of RheumBuilders, a new community of monthly donors, and the relaunch of its Legacy Society, a community of donors who have included the Foundation in their wills or estate plans. These initiatives are designed to deepen the Foundation’s commitment to rheumatology research and patient care,…
In 2016, as part of the Simple Tasks campaign, the ACR established September as Rheumatic Disease Awareness Month (RDAM) to draw attention to the 100-plus conditions under the rheumatic disease umbrella. The goal of RDAM is not only to raise public awareness, but also to increase understanding about the symptoms, risk factors, treatment options, economic…